Information Provided By:
Fly News Breaks for March 10, 2015
BAYRY, AZN, ABBV, GSK, LLY, PFE, BMY, RHHBY, PCYC
Mar 10, 2015 | 08:08 EDT
Jefferies says AbbVie (ABBV) remains its Top Global Pick in Pharmaceuticals on its belief the Pharmacyclics (PCYC) deal will be an inflection point for the stock. Pfizer (PFE) remains the firm's second pick and AstraZeneca (AZN) third, with the latter being promoted to Top European Pick. Roche (RHHBY) is in the fourth spot and Eli Lilly (LLY) has been moved to fifth in place of Bayer (BAYRY) which dropped to eighth. Bristol-Myers (BMY) and GlaxoSmithKline (GSK) are Jefferies' least preferred stocks in the space.
News For ABBV;PCYC;PFE;AZN;RHHBY;LLY;BAYRY;BMY;GSK From the Last 2 Days
ABBV
Jan 18, 2019 | 16:33 EDT
AbbVie (ABBV) announced an update on the Phase 3 RESOLVE trial of ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma (cancer). Metastatic pancreatic cancer is an aggressive and difficult-to-treat solid tumor primarily treated with chemotherapy today. IMBRUVICA is a first-in-class Bruton's tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech (JNJ). IMBRUVICA has been available in the U.S. since 2013 and is FDA-approved for use in five B-cell blood cancers, as well as in chronic graft-versus-host-disease for a total of nine FDA-approved indications. PCYC-1137 evaluated the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer. Patients were randomized 1:1 to receive ibrutinib and nab-paclitaxel and gemcitabine combination treatment arm versus the placebo and nab-paclitaxel and gemcitabine combination treatment arm . At conclusion, the study did not meet its primary endpoint of improving progression-free survival or overall survival benefit among the study population. Safety data collected from the study were consistent with the existing safety information for the study therapies. The full results from this trial will be submitted for publication to a future scientific conference and/or a peer-reviewed medical journal.
AZN
Jan 18, 2019 | 14:30 EDT
LLY
BMY
LLY, PFE, RHHBY, GSK, BMY, AZN
LLY
Jan 18, 2019 | 08:08 EDT
Aimmune Therapeutics (AIMT) announced the appointment of Andrew Oxtoby as Chief Commercial Officer. Oxtoby, a proven pharmaceutical executive with two decades of experience in the healthcare and consumer products industries, will join Aimmune in the newly created role on Tuesday, January 22. Oxtoby joins Aimmune from Eli Lilly (LLY), where he most recently had responsibility for Lilly's U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins
AZN
Jan 18, 2019 | 07:03 EDT
AstraZeneca (AZN) announced that its partner Ironwood Pharmaceuticals (IRWD) has received marketing authorization from the National Medical Products Administration for Linzess in China for the treatment of adult patients with irritable bowel syndrome with constipation, or IBS-C. Launch of Linzess in China is expected in the second half of 2019. Under the terms of the collaboration, AstraZeneca will record Product Sales and share the net profits and losses associated with Linzess in China, with AstraZeneca carrying 55% of each until a certain specified milestone is achieved, moving to a 50/50 split thereafter. Ironwood will also be eligible for up to $125M in additional commercial milestone payments contingent on the achievement of certain sales targets.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.